Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships. / Druedahl, Louise C.; Minssen, Timo; Price II, William Nicholson.

In: Vaccine, Vol. 39, No. 42, 08.10.2021, p. 6291 - 6295.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Druedahl, LC, Minssen, T & Price II, WN 2021, 'Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships', Vaccine, vol. 39, no. 42, pp. 6291 - 6295. <https://www.sciencedirect.com/science/article/pii/S0264410X21011634>

APA

Druedahl, L. C., Minssen, T., & Price II, W. N. (2021). Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships. Vaccine, 39(42), 6291 - 6295. https://www.sciencedirect.com/science/article/pii/S0264410X21011634

Vancouver

Druedahl LC, Minssen T, Price II WN. Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships. Vaccine. 2021 Oct 8;39(42):6291 - 6295.

Author

Druedahl, Louise C. ; Minssen, Timo ; Price II, William Nicholson. / Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships. In: Vaccine. 2021 ; Vol. 39, No. 42. pp. 6291 - 6295.

Bibtex

@article{b6ee431993db45bc8812c71fe8b865c7,
title = "Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships",
abstract = "This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next. Volume 39, Issue 42, 8 October 2021, Pages 6291-6295",
keywords = "Faculty of Law, Legal considerations, Pharmaceutical policy, COVID-19, Vaccine, knowledge sharing, empirical legal studies, empirical research",
author = "Druedahl, {Louise C.} and Timo Minssen and {Price II}, {William Nicholson}",
year = "2021",
month = oct,
day = "8",
language = "English",
volume = "39",
pages = "6291 -- 6295",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "42",

}

RIS

TY - JOUR

T1 - Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships

AU - Druedahl, Louise C.

AU - Minssen, Timo

AU - Price II, William Nicholson

PY - 2021/10/8

Y1 - 2021/10/8

N2 - This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next. Volume 39, Issue 42, 8 October 2021, Pages 6291-6295

AB - This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next. Volume 39, Issue 42, 8 October 2021, Pages 6291-6295

KW - Faculty of Law

KW - Legal considerations

KW - Pharmaceutical policy

KW - COVID-19

KW - Vaccine

KW - knowledge sharing

KW - empirical legal studies

KW - empirical research

M3 - Journal article

VL - 39

SP - 6291

EP - 6295

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -

ID: 276122727